DALIRESP

Daliresp Adverse Events Reported to the FDA Over Time

How are Daliresp adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Daliresp, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Daliresp is flagged as the suspect drug causing the adverse event.

Most Common Daliresp Adverse Events Reported to the FDA

What are the most common Daliresp adverse events reported to the FDA?

Diarrhoea	51 (4.42%)
Insomnia	43 (3.73%)
Nausea	43 (3.73%)
Decreased Appetite	42 (3.64%)
Weight Decreased	37 (3.21%)
Dyspnoea	35 (3.03%)
Dizziness	32 (2.77%)
Headache	30 (2.6%)
Suicidal Ideation	26 (2.25%)
Tremor	26 (2.25%)
Anxiety	24 (2.08%)
	Show More
Back Pain	21 (1.82%)
Asthenia	17 (1.47%)
Vomiting	17 (1.47%)
Chest Pain	15 (1.3%)
Abdominal Pain	14 (1.21%)
Chronic Obstructive Pulmonary Disea...	14 (1.21%)
Off Label Use	14 (1.21%)
Condition Aggravated	13 (1.13%)
Influenza Like Illness	12 (1.04%)
Muscular Weakness	12 (1.04%)
Pain	12 (1.04%)
Frequent Bowel Movements	11 (.95%)
Death	10 (.87%)
Fatigue	10 (.87%)
Swelling Face	10 (.87%)
Mood Altered	9 (.78%)
Palpitations	9 (.78%)
Panic Attack	9 (.78%)
Pneumonia	9 (.78%)
Depression	8 (.69%)
Oedema Peripheral	8 (.69%)
Tachycardia	8 (.69%)
Abdominal Pain Upper	7 (.61%)
Atrial Fibrillation	7 (.61%)
Cold Sweat	7 (.61%)
Dehydration	7 (.61%)
Malaise	7 (.61%)
Rash	7 (.61%)
Blood Pressure Increased	6 (.52%)
Convulsion	6 (.52%)
Drug Interaction	6 (.52%)
Dry Mouth	6 (.52%)
Gastrooesophageal Reflux Disease	6 (.52%)
Hallucination	6 (.52%)
Heart Rate Increased	6 (.52%)
Pain In Extremity	6 (.52%)
Paraesthesia	6 (.52%)
Ventricular Tachycardia	6 (.52%)
Bronchitis	5 (.43%)
Delusion	5 (.43%)
Drug Ineffective	5 (.43%)
Dysgeusia	5 (.43%)
Fall	5 (.43%)
Mental Status Changes	5 (.43%)
Mood Swings	5 (.43%)
Pancreatitis Acute	5 (.43%)
Accidental Overdose	4 (.35%)
Ageusia	4 (.35%)
Anger	4 (.35%)
Arthralgia	4 (.35%)
Blood Glucose Increased	4 (.35%)
Eructation	4 (.35%)
Fear	4 (.35%)
Lethargy	4 (.35%)
Liver Function Test Abnormal	4 (.35%)
Muscle Spasms	4 (.35%)
Orthostatic Hypotension	4 (.35%)
Psychotic Disorder	4 (.35%)
Renal Failure Acute	4 (.35%)
Respiratory Tract Congestion	4 (.35%)
Abnormal Dreams	3 (.26%)
Arrhythmia	3 (.26%)
Cardiac Arrest	3 (.26%)
Depressed Mood	3 (.26%)
Dyspepsia	3 (.26%)
Heart Rate Decreased	3 (.26%)
Hypotension	3 (.26%)
International Normalised Ratio Incr...	3 (.26%)
Irritability	3 (.26%)
Melaena	3 (.26%)
Nervousness	3 (.26%)
Overdose	3 (.26%)
Oxygen Saturation Decreased	3 (.26%)
Presyncope	3 (.26%)
Pruritus	3 (.26%)
Suicide Attempt	3 (.26%)
Supraventricular Tachycardia	3 (.26%)
Syncope	3 (.26%)
Therapeutic Response Unexpected	3 (.26%)
Abdominal Discomfort	2 (.17%)
Abdominal Distension	2 (.17%)
Aggression	2 (.17%)
Agitation	2 (.17%)
Angioedema	2 (.17%)
Appendicitis	2 (.17%)
Blister	2 (.17%)
Blood Bilirubin Increased	2 (.17%)
Blood Glucose Decreased	2 (.17%)
Brain Scan Abnormal	2 (.17%)
Bruxism	2 (.17%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Daliresp, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Daliresp is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Daliresp

What are the most common Daliresp adverse events reported to the FDA?

Gastrointestinal Signs	96 (8.32%)
Gastrointestinal Motility And Defec...	70 (6.07%)
Neurological	61 (5.29%)
Respiratory	53 (4.59%)
Sleep Disorders	50 (4.33%)
Anxiety Disorders	43 (3.73%)
Appetite And General Nutritional	42 (3.64%)
Cardiac Arrhythmias	38 (3.29%)
Physical Examination Topics	38 (3.29%)
Suicidal And Self-injurious Behavio...	31 (2.69%)
Headaches	30 (2.6%)
	Show More
Movement Disorders	27 (2.34%)
Musculoskeletal And Connective Tiss...	27 (2.34%)
Epidermal And Dermal Conditions	25 (2.17%)
Infections - Pathogen Unspecified	21 (1.82%)
Cardiac And Vascular Investigations	19 (1.65%)
Mood Disorders	19 (1.65%)
Bronchial Disorders	18 (1.56%)
Muscle	18 (1.56%)
Therapeutic Procedures And Supporti...	16 (1.39%)
Therapeutic And Nontherapeutic Effe...	15 (1.3%)
Disturbances In Thinking	14 (1.21%)
Depressed Mood Disorders	11 (.95%)
Electrolyte And Fluid Balance Condi...	10 (.87%)
Fatal Outcomes	10 (.87%)
Hepatobiliary	10 (.87%)
Medication Errors	10 (.87%)
Cardiac Disorder Signs	9 (.78%)
Decreased And Nonspecific Blood Pre...	9 (.78%)
Metabolic, Nutritional And Blood Ga...	9 (.78%)
Hematology Investigations	8 (.69%)
Psychiatric	8 (.69%)
Skin Appendage Conditions	8 (.69%)
Exocrine Pancreas Conditions	7 (.61%)
Gastrointestinal Hemorrhages	7 (.61%)
Renal Disorders	7 (.61%)
Injuries	6 (.52%)
Salivary Gland Conditions	6 (.52%)
Seizures	6 (.52%)
Personality Disorders	5 (.43%)
Schizophrenia And Other Psychotic	5 (.43%)
Central Nervous System Vascular	4 (.35%)
Changes In Physical Activity	4 (.35%)
Coronary Artery	4 (.35%)
Heart Failures	4 (.35%)
Joint	4 (.35%)
Mental Impairment	4 (.35%)
Oral Soft Tissue Conditions	4 (.35%)
Angiedema And Urticaria	3 (.26%)
Bone And Joint Injuries	3 (.26%)
Diverticular	3 (.26%)
Gallbladder	3 (.26%)
Gastrointestinal Inflammatory Condi...	3 (.26%)
Neurological, Special Senses And Ps...	3 (.26%)
Psychiatric And Behavioural Symptom...	3 (.26%)
Vision	3 (.26%)
Water, Electrolyte And Mineral	3 (.26%)
Allergic Conditions	2 (.17%)
Dental And Gingival Conditions	2 (.17%)
Fungal Infectious	2 (.17%)
Gastrointestinal	2 (.17%)
Gastrointestinal Conditions	2 (.17%)
Impulse Control	2 (.17%)
Lifestyle Issues	2 (.17%)
Lower Respiratory Tract Disorders	2 (.17%)
Manic And Bipolar Mood Disorders	2 (.17%)
Myocardial	2 (.17%)
Peripheral Neuropathies	2 (.17%)
Renal And Urinary Tract Investigati...	2 (.17%)
Skin Neoplasms Malignant And Unspec...	2 (.17%)
Structural Brain	2 (.17%)
Tongue Conditions	2 (.17%)
Urinary Tract Signs	2 (.17%)
Vascular	2 (.17%)
Vascular Inflammations	2 (.17%)
White Blood Cell	2 (.17%)
Abdominal Hernias And Other Abdomin...	1 (.09%)
Acid-base	1 (.09%)
Bone Disorders	1 (.09%)
Breast	1 (.09%)
Cardiac Therapeutic Procedures	1 (.09%)
Cranial Nerve Disorders	1 (.09%)
Deliria	1 (.09%)
Gastrointestinal Stenosis And Obstr...	1 (.09%)
Gastrointestinal Vascular Condition...	1 (.09%)
Hepatic And Hepatobiliary	1 (.09%)
Inner Ear And Viiith Cranial Nerve	1 (.09%)
Lipid Metabolism	1 (.09%)
Procedural And Device Related Injur...	1 (.09%)
Protein And Chemistry Analyses	1 (.09%)
Sleep Disturbances	1 (.09%)
Soft Tissue Neoplasms Benign	1 (.09%)
Thyroid Gland	1 (.09%)
Toxicology And Therapeutic Drug Mon...	1 (.09%)
Vascular Hemorrhagic	1 (.09%)
Viral Infectious	1 (.09%)
Vulvovaginal Disorders	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Daliresp, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Daliresp is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.